About champions oncology - CSBR
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
CSBR At a Glance
Champions Oncology, Inc.
One University Plaza
Hackensack, New Jersey 07601
| Phone | 1-201-808-8400 | Revenue | 59.43M | |
| Industry | Biotechnology | Net Income | -1,175,000.00 | |
| Sector | Health Technology | 2026 Sales Growth | 4.357% | |
| Fiscal Year-end | 04 / 2027 | Employees | 214 | |
| View SEC Filings |
CSBR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.387 |
| Price to Book Ratio | 21.012 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 236.483 |
| Enterprise Value to Sales | 1.385 |
| Total Debt to Enterprise Value | 0.056 |
CSBR Efficiency
| Revenue/Employee | 277,686.916 |
| Income Per Employee | -5,490.654 |
| Receivables Turnover | 4.509 |
| Total Asset Turnover | 2.003 |
CSBR Liquidity
| Current Ratio | 0.965 |
| Quick Ratio | 0.965 |
| Cash Ratio | 0.245 |
CSBR Profitability
| Gross Margin | 45.684 |
| Operating Margin | -1.732 |
| Pretax Margin | -1.563 |
| Net Margin | -1.977 |
| Return on Assets | -3.961 |
| Return on Equity | -30.476 |
| Return on Total Capital | -13.764 |
| Return on Invested Capital | -15.231 |
CSBR Capital Structure
| Total Debt to Total Equity | 116.73 |
| Total Debt to Total Capital | 53.86 |
| Total Debt to Total Assets | 17.037 |
| Long-Term Debt to Equity | 76.136 |
| Long-Term Debt to Total Capital | 35.129 |